On Monday, Altria Group Inc (NYSE:MO)’s shares inclined 0.41% to $55.72.
Altria Group, Inc. (Altria) (MO) is hosting an investor day conference in New York City recently. Marty Barrington, Altria’s Chairman, Chief Executive Officer and President, and other members of Altria’s senior administration team will highlight Altria’s unique capabilities, its companies’ strong brands and strategies to create long-term value for shareholders.
2015 Full-Year Guidance
Altria reaffirms its guidance for 2015 full-year adjusted diluted earnings per share (EPS), which excludes the special items talk about in Plan 1, to be in the range of $2.75 to $2.80, representing a growth rate of 7% to 9% from an adjusted diluted EPS base of $2.57 in 2014, as shown in Plan 1.
The factors described in the Forward-Looking and Cautionary Statements section of this release represent ongoing risks to Altria’s forecast.
Altria Group, Inc., through its auxiliaries, manufactures and sells cigarettes, smokeless products, and wine in the United States and internationally. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, Husky, and Marlboro Snus brand names.
Tenaris SA (ADR) (NYSE:TS)’s shares gained 5.66% to $26.90.
Tenaris SA (ADR) (TS) declares that, following the formerly declared restatement of its quarterly merged financial statements as of September 30, 2014, its annual merged financial statements as of December 31, 2014, and its quarterly merged financial statements as of March 31, 2015, to reflect a lower carrying value of its investments in Usiminas, it has filed with the U.S. Securities and Exchange Commission (SEC) its annual report on Form 20-F for the year ended December 31, 2014, and has presented to the SEC its restated quarterly and annual financial statements. As a consequence of the restatement of the merged financial statements as of December 31, 2014, the Company has also filed with the Luxembourg Stock Exchange a restated annual report on the merged financial statements for the year ended December 31, 2014, prepared in accordance with applicable Luxembourg law requirements, and has presented such restated annual report to the other securities regulators of the markets where its securities are listed.
Tenaris S.A., through its auxiliaries, manufactures and supplies steel pipe products and related services for the energy and other industrial applications. It offers products for oil and gas drilling operations that comprise casings and tubings, premium connections, drill pipes, coiled tubing, hot-rolled and cold-drawn tubes, tubular and non-tubular accessories, and devices, in addition to technical consulting, pipe administration, and field services
At the end of Monday’s trade, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)‘s shares dipped -3.95% to $7.30.
Achillion Pharmaceuticals, Inc. (ACHN) declared that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102) on the pharmacokinetics of AL-335 in healthy volunteers.
This phase I study is an open-label, two-group study of simeprevir and odalasvir, a HCV NS5A inhibitor, on the pharmacokinetics of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which accomplished Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which accomplished Phase II clinical trial.
Vereit Inc (NYSE:VER), ended its Monday’s trading session with -0.35% loss, and closed at $8.66.
VEREIT, Inc. (VER) declared its operating results for the three months ended June 30, 2015, details on its business plan and enhancements to its corporate governance.
Second Quarter 2015 Merged Financial Results
Revenue
Merged revenue for the quarter ended June 30, 2015 raised $11.5 million to $393.7 million as contrast to revenue of $382.2 million for the same quarter in 2014.
Net Loss
Merged net loss for the quarter ended June 30, 2015 raised $52.1 million to $(108.7) million as contrast to a net loss of $(56.6) million for the same quarter in 2014.
Normalized EBITDA
Merged normalized EBITDA for the quarter ended June 30, 2015 raised $17.6 million to $309.3 million as contrast to normalized EBITDA of $291.7 million for the same quarter in 2014.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
